Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 17/20 | 0.61 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.48 |
| ▸ | PLA2G2E | Q9NZK7 | 3/20 | 0.48 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.48 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7009863 | 0.96 | PLA2G1B (0.66) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL8022953 | 0.91 | PLA2G1B (0.64) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL7013828 | 0.86 | PLA2G1B (0.67) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL7238890 | 0.85 | PLA2G1B (0.63) | PLA2G1BPLA2G2A | |
| SCHEMBL7010713 | 0.83 | PLA2G1B (0.64) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL7011531 | 0.83 | PLA2G1B (0.64) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL8324082 | 0.83 | PLA2G1B (0.47) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL7047797 | 0.79 | PLA2G1B (0.94) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 | |
| SCHEMBL7014306 | 0.78 | PLA2G1B (0.61) | PLA2G1BPLA2G2A | |
| SCHEMBL7011194 | 0.78 | PLA2G1B (0.86) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1037630-A2 | METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 2000-09-27 | — | — | EP | claimed |
| EP-0977566-A1 | METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 2000-02-09 | — | — | EP | claimed |
| WO-1999024026-A2 | METHOD FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH APOPTOSIS USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1999-05-20 | — | — | WO | claimed |
| WO-1998047508-A1 | METHOD FOR THE TREATMENT OF STROKE USING N-HETEROCYCLIC GLYOXYLAMIDE COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1998-10-29 | — | — | WO | claimed |
| US-6645976-B1 | Nonpancreatic secretory phospholipase (sPLA2) supressors such as 2-(3-Benzyl-8-hydroxy-2-ethylindolizin-1-yl)acetamide, administered to control release of fatty acid and prevent the arachidonic acid cascade; septic shock | ELI LILLY AND COMPANY | 2003-11-11 | — | — | US | disclosed |
| EP-0772596-B1 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | disclosed |
| EP-0772596-A4 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0772596-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003383-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |